Compare TG Therapeutics Inc (TGTX) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Wipro Limited — how do they compare? TG Therapeutics Inc trades at $55.11 (market cap $8.16B), while Wipro Limited trades at $1.71 (market cap $16.22B). The key difference: Wipro Limited is the larger of the two by market cap, and Wipro Limited pays a 5.19% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Wipro Limited for 41 Days on average.
| TGTX | WIT | |
|---|---|---|
Market Cap | $8.16B | $16.22B |
Volume | 1,735,121 | 9,028,667 |
Sector | Health | Technology |
52-Week High | $59.06 | $3.06 |
52-Week Low | $26.94 | $1.61 |
Typical Hold Time | 16 Days | 41 Days |
Enterprise Value | $8.37B | $14.33B |
Dividend Yield | — | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
WIT trades at $1.70, up 1.8% today, but technical indicators are bearish with recent earnings misses. The company reported Q1 2027 revenue below expectations, though annual net income improved to $131.35B in 2025. Positive news includes AI-driven productivity gains and new cybersecurity partnerships, but analyst sentiment is mixed with a majority hold rating.
The outlook is cautious due to earnings volatility and competitive pressures, though valuation ratios like P/E of 12.78 appear reasonable. Key risks include client spending cuts and margin pressure from wage increases. Upside depends on execution of AI initiatives and large deal ramp-ups stabilizing financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
